A Phase 2 interventional study of SFG-02 and Placebo in Participants With Underactive Bladder (UAB), sponsored by Juro Sciences Inc.. Recruiting at 16 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by Juro Sciences Inc. · Phase 2, Interventional, and Treatment
The objective of this POC (Phase 2a) study is to evaluate the effect on Bladder Voiding Efficiency (BVE) as well as safety of SFG-02 transdermal formulation in participants with UAB.
Participants will:
31 studies on the registry are indexed under Urinary Bladder, Underactive; 6 are open to participants now.
This study's planned enrollment of 70 is close to the median of 66 across 21 interventional studies indexed under Urinary Bladder, Underactive.
Browse Urinary Bladder, Underactive studies →Juro Sciences Inc. is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
4-Week Placebo Run-in Period followed by SFG-02 Application for 8 weeks
Drug: SFG-02
4-Week Placebo Run-in Period followed by Placebo Application for 8 weeks
Drug: Placebo
Transdermal formulation containing SFG-02 1.6 mg once a day
placebo once a day
Bladder Voiding Efficiency (BVE)
BVE is calculated by a fraction (%) of bladder volume evacuated (\[voided volume\]/\[bladder volume prior to voiding\] × 100).
Time frame: The change from Baseline (Week 4) to Week 12
Plan to share: No
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Urinary Bladder, Underactive →
Juro Sciences Inc.